In summary, this review has shown that, although synthetic SGLT2 inhibitors effectively promote glucosuria and improve glycemic control in T2DM, their clinical utility is constrained by risks of genitourinary infection and limited metabolic benefits. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.